Beta-Lactams

PreclinicalSmall molecule

NNational Taiwan University Hospital

Beta-Lactams is one of 9 small molecule programs targeting Critically Ill Patients. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Critically Ill PatientsUnknown status

Critically Ill PatientsPreclinical

Unknown status

Competition

Competitive Landscape

14 competitors in Critically Ill Patients

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

3 2

Depo-Testosterone

AAzurity Pharmaceuticals

Approved

1 3

Treatment With CAZ-AVI

SSoutheast University, China

Phase 3

1 4

Prostigmin

Merck & Co.

Preclinical

2 5

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Preclinical

1 6

Magnesium

SSpherium Biomed

Preclinical

1 7

Fufang E'jiao Jiang

XXiyuan Hospital of China Academy of Chinese Medical Sciences

Preclinical

1 8

Degludec Insulin

Sunshine Lake Pharma Co., Ltd.

Preclinical

1 9

Beta-Lactams

NNational Taiwan University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Critically Ill Patients1 trial

Evaluation of Extended Intravenous of Beta-lactams in the Treatment of Serious Gram-negative Infections in Critically Ill Patients

Unknown status·NNational Taiwan University Hospital·N/A·NCT01600768·100 enrolled

Antibiotic Therapy1 trial

Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD

Completed·HHaiphong University of Medicine and Pharmacy·Phase 2/3·NCT04879030·170 enrolled

Pneumonia1 trial

Short Duration Treatment of Non-severe Community Acquired Pneumonia

Unknown status·VVersailles Hospital·Phase 2·NCT01963442·310 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Beta-Lactams. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Beta-Lactams compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Beta-Lactams. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Taiwan University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Taiwan University Hospital

Beta-Lactams

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Critically Ill Patients1 trial

Antibiotic Therapy1 trial

Pneumonia1 trial

References

Drug Info

Quick Facts

Related News